University of California Berkeley and Glass House Collaboration Leads to State-Funded Research on Cannabis Crop Yields
LONG BEACH, Calif. and TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")...
Day: January 13, 2026
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study.No treatment limiting toxicities reported.Patient...
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical...
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an...
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis...
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company...
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader...
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma...
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and...
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 13, 2026...
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough...
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Debt-Free Balance Sheet With $21.6 Million in CashBROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the...
Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and...
Bio Usawa Receives Ghana FDA Approval for BioUcenta™
Ghana follows Rwanda in approving BioUcenta™, Africa’s first approved ranibizumab biosimilarACCRA, Ghana and KIGALI, Rwanda, Jan. 13, 2026 (GLOBE NEWSWIRE)...
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes...
Basilea joins INCATE to support antifungal innovation
Allschwil, Switzerland, January 13, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs...
Checkerspot and La Fabrique Végétale Partner to Commercialize Algal Oils in the European Personal Care Market
Fermentation-Derived Algal Oils Meet Their Moment as Next-Generation Ingredients for European Cosmetic and Personal Care BrandsAlameda, Calif (USA) and Lyon...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences
Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences...
Metabo Drops 2026: Is It Legit? Ingredients, Safety Facts, and Consumer Analysis
Consumer searches for supplement legitimacy increased 26% year-over-year as transparency becomes central purchasing criterion — industry analysis examines what drives...